

1 Mammary Stem Cells: Premise, Properties and Perspectives

2

3 Bethan Lloyd-Lewis^{1,#*} Olivia B. Harris^{1,2}, Christine J. Watson^{1,2}, Felicity M. Davis^{3,4*}

4

5 ¹Department of Pathology, University of Cambridge, Cambridge, CB2 1QP, UK, ²Wellcome Trust-Medical

6 Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 1QR, UK,

7 ³School of Pharmacy, The University of Queensland, Brisbane, 4102, Australia, ⁴Mater Research Institute,8 The University of Queensland, Brisbane, 4102, Australia. [#]Current address: Department of Genetics and9 Developmental Biology, Institut Curie, Paris, France. *Correspondence: f.davis@uq.edu.au (F.M. Davis) and10 bethan.lloyd-lewis@curie.fr (B. Lloyd-Lewis).

11

12

13 **Keywords**

14 Adult mammary stem cells, mammary gland development, lineage-tracing, breast cancer, cancer stem cells.

15

16 **Abstract**

17 Adult mammary stem cells (MaSCs) drive postnatal organogenesis and remodeling in the mammary gland,

18 and their longevity and potential have important implications for breast cancer. However, despite intense

19 investigation, the identity, location and differentiation potential of MaSCs remains subject to deliberation. The

20 application of genetic lineage-tracing models, combined with quantitative 3-dimensional imaging and

21 biophysical methods, has provided new insights into the mammary epithelial hierarchy that challenges

22 classical definitions of MaSC potency and behaviors. Herein, we review recent advances—discussing

23 fundamental unresolved properties of MaSC potency, dynamics and plasticity—and point to evolving

24 technologies promising to shed new light on this intractable debate. An elucidation of the physiological

25 mammary differentiation hierarchy is paramount to understanding the complex heterogeneous breast cancer

26 landscape.

27

28 **Adult mammary stem cells: concepts and challenges**

29 Adult stem cells exist in various organs, such as the intestine, skin and skeletal muscle [1,2]. In these tissues,
30 their primary role is homeostatic, that is, to replenish cells lost to attrition or injury. However, unlike many
31 other organs, the mammary gland primarily develops postnatally [3,4] (Figure 1), and thus stem cells in the
32 adult mammary gland serve both developmental and homeostatic functions.

33
34 Construction of the branching ductal epithelium during puberty is driven by hormones, growth factors and
35 local signaling cues, and proceeds via proliferation of **mammary stem cells** (MaSCs, see Glossary) and their
36 progeny within bulbous distal structures known as **terminal end buds** (TEBs) (Figure 1b) [5,6]. By the end
37 of puberty, ductal morphogenesis is complete and the TEBs have fully regressed (Figure 1c) [4]. Although it
38 is generally accepted that stem cells persist in the adult mammary gland following the demise of the TEBs—
39 where they have essential roles in the generation and regeneration of the alveolar (milk-producing) epithelium
40 during pregnancy and lactation (Figure 1c-f)—the location of these cells within the complex ductal epithelium
41 remains elusive [6,7]. Additionally, despite intense investigation and debate, the differentiation potential of
42 adult MaSCs (i.e. their ability to generate one or both of the mammary epithelial cell lineages) remains
43 contentious [7–18]. The longevity and extensive self-renewal properties of these cells, however, place them
44 as probable candidates for oncogenic transformation in some breast cancers [19,20]. Moreover, some breast
45 cancers may be hierarchically-organized and contain a pool of cancer stem cells that drive their precipitous
46 and long-term growth and regrowth [19–21]. Thus, a greater understanding of the identity, plasticity and
47 differentiation potential of adult MaSCs, and the specific pathways that regulate their self-renewal and fate,
48 may also provide important insights into the heterogeneity and treatment resistance of this intractable disease.

49
50 Recent studies, using single cell lineage-tracing approaches, have revealed the immense capacity of a single
51 MaSC to contribute to the formation of the ductal epithelium during puberty [16,18] and the alveolar
52 epithelium during pregnancy/lactation [16]. These studies also highlight considerable redundancy within this
53 system [16,18], positing that several hundred lineage-restricted MaSCs actively and stochastically contribute
54 to ductal and alveolar morphogenesis under physiological conditions. This is not entirely surprising, given
55 that lactation is an evolutionarily essential aspect of mammalian survival that demands functional stem cells.
56 However, if MaSCs are the cell-of-origin in some breast cancers, then this superfluity brings with it a heightened
57 opportunity for oncogenic transformation. Regardless, the inextricable connections between MaSCs and breast
58 cancer warrants further investigation, to achieve a unified and enduring characterization of their potential,
59 anatomical location and molecular profile.

60
61 Here, we discuss recent insights into the **mammary epithelial cell hierarchy**, addressing unanswered
62 questions relating to MaSC potency, dynamics and plasticity. We discuss the unique challenges in elucidating

63 the mammary epithelial cell hierarchy and highlight evolving technologies that promise to shed new light on
64 these difficult questions.

66 **The epithelial cell hierarchy: an evolving paradigm**

67 In 1959, a seminal study published in *Cancer Research* demonstrated that fragments of mammary tissue could
68 be transplanted into the epithelium-divested fat pad of a recipient mouse, successfully engraft, and generate
69 an entire ductal epithelium anew [22]. What followed was a divisive pursuit to identify and characterize the
70 cells responsible for the development, maintenance and regeneration of the mammary epithelium (i.e. adult
71 MaSCs) that has lasted for more than 50 years (Figure 2). Transformative advances came on the back of at
72 least three key enabling methodologies: the isolation of cells with enhanced repopulating and self-renewal
73 properties upon transplantation; population-based genetic fate-mapping; and stochastic, single cell genetic
74 lineage-tracing. The ability to image ducts and alveoli in three- [14–16,18,23,24] or four-dimensions [18]
75 (Box 1), combined with quantitative image analysis and biostatistical modeling [5,15,18], has also provided
76 important insights into clonal dynamics and dispersion patterns that could not have been attained through the
77 examination of thin tissue sections [25]. Here, we broadly examine these techniques, summarizing key
78 findings with a retrospective wisdom.

80 *Transplantation*

81 The observation that any fragment of mammary tissue has the potential to regenerate the entire bilayered
82 mammary epithelium upon serial transplantation provided strong evidence that **mammary repopulating cells**
83 (believed to be bona fide MaSCs) were distributed throughout the length of the adult ductal epithelium [26–
84 28]. Subsequent work using retroviral-tagged mammary tissue fragments [29] and limiting dilutions of
85 heterogeneous cell suspensions confirmed these results [30,31], and these studies were in-turn refined and
86 expanded by the identification and purification of a subset of cells with superior repopulating capacity [8–10]
87 (Figure 2). Collectively, these analyses supported the notion that adult MaSCs were **bi/multipotent**. The
88 demonstration that lineage-restricted cells could be forced to adopt a multipotent fate under “regenerative
89 conditions” [11–13] challenged this dogma. It is now widely accepted that mammary repopulating cells,
90 identified by transplantation, are distinct from stem cells that exist under physiological conditions.
91 Nevertheless, this technique has provided some important insights into qualities of self-renewal and
92 regeneration, with enduring relevance.

94 *Population-based genetic fate-mapping*

95 The application of genetic **lineage-tracing** techniques to mammary tissue has enabled temporal examination
96 of lineage relationships under physiological conditions. These studies have utilized tamoxifen- or
97 doxycycline- responsive transgenic mouse models to induce the expression of reporter genes in predefined
98 cohorts of cells [11–15,17]. The genetic label, typically a fluorescent or histochemical reporter, is permanently

99 expressed by the original cell and is transmitted to all of its progeny. An analysis of reporter expression
100 through time can be used to determine whether the original labeled population contained lineage-restricted
101 stem cells or cells with multi-lineage differentiation potential (Figure 2). In its original application in the
102 mammary gland [11], this approach was used to track the fate of **luminal cells** (e.g., cytokeratin (K)8-
103 expressing) and **basal cells** (e.g., K14-expressing), demonstrating that lineage-restricted MaSCs drive
104 postnatal mammary gland development and maintenance. Subsequent lineage-tracing studies have provided
105 evidence in support of both **unipotent** and bi/multipotent adult MaSCs [12–15,17,32] (Figure 2). Lineage-
106 restricted cell populations have also been shown to convert to multipotency *in vivo* by oncogenic PI3KCA
107 signaling, suggesting that there is scope for plastic transformation and thereby adding further complexity to
108 this system [33,34].

109
110 Inconsistencies in recent lineage-tracing studies in the normal mammary gland may be in-part attributable to
111 the temporal expression of pathway-specific promoters [12,13] or the fidelity of pan-lineage promoters. Given
112 that a single mammary stem/progenitor cell is capable of producing many hundred progeny [16], the
113 promiscuous labeling of even a small number of cells of the opposing lineage could significantly confound
114 downstream lineage analysis in this model [15,16]. A second limitation relates to the power of population-
115 based labeling approaches to accurately detect single **clone** expansion, which is a function of both the method
116 of detection and the initial labeling density (Figure 3). To overcome this problem, as well as potential tracing
117 artefacts associated with the preferential labeling of specific (and potentially non-representative) cell sub-
118 populations, a recent study has mapped the fate of all basal cells (a technique termed saturation lineage-
119 tracing) [15]. If rare bipotent MaSCs do reside in the basal compartment and contribute even minimally to
120 mammary gland morphogenesis and homeostasis [1], this could be detected by an increase in the number of
121 fluorescently-labeled luminal cells, observed using both fluorescence activated cell sorting or 3D image
122 quantification. No population flux was detected using either method of analysis in these studies, suggesting
123 that basal MaSCs are indeed lineage-restricted [15]. A subsequent report [35], however, demonstrated that
124 enzymatic digestion prior to 3D imaging [15,18,36,37] can deplete or structurally damage basal cells,
125 postulating that rare bi-lineage clones are not detected under these conditions [35]. Recently described
126 methods for non-proteolytic 3D imaging [16,24], together with quantitative platforms for image analysis,
127 which consider tissue architecture, cell morphology, chimerism and Cre-specificity [15,35], will undoubtedly
128 aid future lineage tracing studies in the mammary gland.

129 *Stochastic, single cell genetic lineage-tracing*

130 Lineage-tracing has facilitated *in situ* examination of MaSC properties under conditions of minimal
131 interference. However, unlike transplantation assays, these studies have been unable to map the fate of a single
132 labeled cell [9]. Obstacles to single cell genetic lineage-tracing have, however, been mitigated in-part by
133 advances in whole-organ clearing [24] and high-resolution 3D imaging [14] (Box 1).
134

135

136 Recently, R26^{[CA]30} mice [38] have been used to achieve unbiased labeling of single proliferating cells in the
137 mammary gland [16]. Genetic labeling in this model is exceedingly rare, and thus it can be combined with 3D
138 imaging to track the fate of a single labeled cell with confidence (Figure 2). A similar approach to achieve
139 low-density, unbiased labeling involves the use of mice that express inducible Cre-recombinase in all cells
140 (R26^{CreERT2}). Neutral, multi-color labeling is achieved by crossing these mice with R26^{Confetti} animals, and
141 sparse reporter induction is attained using low doses of tamoxifen [16,18]. Recent application of these models
142 has provided further evidence that unipotent MaSCs drive ductal morphogenesis during puberty [16,18] and
143 alveolar morphogenesis during gestation [16]. However, whilst the small number of cells initially labeled in
144 these models permit the indisputable analysis of clonal progeny, it also limits their power to detect and
145 characterize the full spectrum of stem and progenitor cells present in the mammary epithelium. For example,
146 quiescent bi/multipotent MaSCs, if they exist, would not be detected by this approach [16].

147

148 Single cell lineage-tracing has unquestionably demonstrated the immense capacity of unipotent stem cells to
149 contribute to the development of the adult mammary epithelium, whilst at the same time revealing significant
150 redundancy in the construction of each major duct [16,18] and lobuloalveolar structure [16]. Whether adult
151 stem cells work cooperatively or competitively to achieve developmental and morphogenetic outcomes in the
152 mammary gland is an area of active investigation and is discussed in more detail later in this review.

153

154 **Multiplicity in the mammary gland: roles for potential and quiescent stem cells**

155 In addition to the cells that are responsible for the genesis and expansion of the mammary epithelium (known
156 as professional, functional or bona fide stem cells), there may also exist a population of cells in the adult breast
157 with the capacity to behave as stem cells under certain conditions (i.e. facultative or **potential stem cells**)
158 [1,39]. This may include 1) a subset of cells that remain quiescent during normal tissue development, and 2)
159 cells that are recruited under regenerative conditions [9,11,40] or in cancer [33,34]. Support for a cellular
160 arrangement in the breast that departs from a unidirectional, top-down model is given by transplantation
161 studies. Although it is now generally accepted that mammary repopulating cells are activated under non-
162 homeostatic conditions [11–13], the underlying experimental observation (i.e. that not all cells are capable of
163 repopulating the empty fat-pad [8–10]) points to the existence of a population of cells that have an intermediate
164 or plastic nature. The physiological and pathological role of these cells, and their relationship to putative
165 populations of quiescent MaSCs, is not immediately apparent (Figure 4). However, the notion that fate
166 decisions within the hierarchy are not strictly unidirectional, and in some conditions could be reversed, has
167 wide-reaching implications for oncology and regenerative medicine.

168

169 *A putative population of quiescent MaSCs*

170 A pool of quiescent stem cells, which have temporarily and reversibly exited the cell cycle, has been observed
171 in various self-renewing tissues, including the skin [41–43] and intestine [44]. These cells may be able to re-
172 enter the cell cycle when required, for example upon injury [45] or homeostasis [46]. Quiescent stem cells are
173 unlikely to be detected by conventional lineage-tracing approaches, which require proliferation for clone
174 identification [47]. As such, label-retention assays have been developed for the analysis of slow-cycling and
175 quiescent cells [48]. DNA-intercalating nucleosides (e.g., BrdU/EdU and [³H]-thymidine) can be used to label
176 cells that are in cycle at the time of the pulse [47]. Alternatively, a GFP-labeled histone H2B model could be
177 used to label specific populations of cells, with expression of H2B-GFP temporally-moderated by
178 administration of doxycycline [43,48,49]. Cells that remain labeled after a pre-determined chase, known as
179 **label-retaining cells**, are presumed to be slow-cycling/quiescent stem cells, but may also be long-lived
180 terminally-differentiated cells [48]. Application of the H2B-GFP model to the mammary gland has identified
181 a novel population of Cd1d⁺ cells with enhanced repopulating ability upon transplantation [49]. Cd1d⁺
182 mammary repopulating cells are also enriched for Bcl11b expression, a C2H2 zinc finger transcription factor
183 that has independently been shown to be associated with physiological quiescence and superior repopulating
184 activity under transplantation conditions [50]. Interestingly, neither Cd1d nor Bcl11b mRNAs are enriched in
185 the recently-identified quiescent basal cell population defined by Lgr5 and Tspan8 expression [51]. These
186 Lgr5⁺Tspan8^{hi} basal cells, located within the proximal ductal tree, were also demonstrated to have enhanced
187 repopulating activity in limiting dilution transplantation assays [51]. Thus, these data suggest significant
188 multiplicity, even within the putative subset of quiescent mammary repopulating cells.

189 *Unanswered questions: organization, function and recruitment*

190 The proliferative demand on mammary stem and progenitor cells throughout reproductive life is substantial
191 (Figure 1) [3,4]. Thus, the relative importance of quiescent MaSCs in normal development and homeostasis
192 is unclear. How quiescent and potential stem cells may be recruited by specific signals in the
193 microenvironment, and their hierarchical relationship to functional stem cells is also shrouded in uncertainty.
194 In light of the ongoing debate regarding the identity and potency of MaSCs [11–18], the fundamental
195 requirement for proliferation for clone detection in lineage-tracing studies [47], and the idea that quiescent
196 stem cells may reside at the apex of tissue hierarchies [49], one could reasonably suggest that there may be a
197 residual population of quiescent bi/multipotent MaSCs that remain in the postnatal mammary gland after
198 embryonic development (Figure 4). *In utero* DNA-labeling has provided some support for this hypothesis,
199 identifying long-lived label-retaining cells that are able to reversibly re-enter the cell cycle and contribute to
200 tissue development and maintenance [46]. More-recent saturation lineage-tracing, which has been able to label
201 more than 95% of all cells within a single lineage, however, indicates that quiescent MaSCs (if they exist and
202 participate in any way to tissue development and/or homeostasis), are lineage-restricted [15]. Analysis of cell
203 division kinetics and telomere lengths in mammary epithelial populations also suggests that that each lineage
204 is maintained by its own precursors throughout reproductive life [52].
205

206
207 A number of important questions in this area remain unanswered. However, given the complex cellular
208 heterogeneity in breast cancer, a long-lived and highly plastic stem cell could serve as a potential cell-of-origin
209 for this disease. This highlights the importance of determining the full landscape of MaSC populations and
210 the factors regulating their recruitment.

211 **The mammary stem cell niche: an elusive entity or dynamic force?**

212 The ability of MaSCs to rapidly and faithfully respond to developmental and homeostatic demands throughout
213 reproductive life may be attributable to their intimate association with a specific cellular microenvironment,
214 known as the mammary **stem cell niche**. Stem cell niches can embody discrete and highly-specialized sites in
215 certain tissues, e.g., the crypt base of the small intestine and the hair follicle [2]. Other tissues, including the
216 post-pubescent mammary gland, prostate and lung, lack an easily-discernable niche, and stem cells in these
217 organs may instead respond to more-ubiquitous tissue signals [2]. In any case, reciprocal interactions between
218 MaSCs and their mature epithelial progeny, neighboring stromal cells and the supporting extracellular matrix,
219 undoubtedly provide the autocrine, juxtacrine and paracrine signals that direct and adjust cell fate [19].
220 Extrinsic regulatory cues may include diffusible molecules (e.g., growth factors and cytokines) as well as
221 mechanical forces (e.g., cell-cell and cell-matrix interactions) [53,54]. In this section, we outline designs of
222 mammary stem and progenitor cell distribution in the pubescent, mature and secretory epithelium, discussing
223 how the spatial arrangement of these cells may underpin the development and integrity of this highly dynamic
224 tissue.
225

226 *Architectural conceptions of a MaSC niche*

227 The absence of a definitive molecular portrait of MaSCs, combined with uncertainties regarding their precise
228 location within the post-pubescent mammary epithelium, has greatly impeded the analysis of prospective
229 MaSC niches. Cell surface signatures that facilitate the isolation of mammary repopulating cells also provide
230 little insight into the tissue-positional cues that direct cell behavior. Early transplantation and ultrastructural
231 studies, however, did imply that mammary repopulating cells were distributed throughout the ductal
232 epithelium [26–28,55], positing that MaSC niches may reside in a “suprabasal” location in the epithelial
233 bilayer [27,56,57].
234

235
236 Although the precise location of stem cells within the post-pubescent breast remains unclear (Figure 1c), it is
237 generally accepted that the TEBs of elongating ducts serve as a transient niche during puberty (Figure 1b)
238 [5,19]. Thus, a comprehensive examination of signaling events in TEB-resident stem cells is expected to yield
239 important insights into the pathways directing MaSC activity and fate, which may also be relevant in the post-
240 pubescent gland. TEBs consist of an outer layer of cap cells that envelop multiple layers of inner body cells
241 [3]. Cap and body cells are generally considered to be the precursors of mature basal and luminal epithelial

242 lineages, respectively [19]. Cap cells have also long been hypothesized to represent an enriched population of
243 bi/multipotent MaSCs [27,58,59]. Indeed, the stem cell associated phosphatase gene *s-Ship*, which is
244 exclusively expressed in cap cells during puberty, correlates with enhanced mammary repopulating capacity
245 in limiting dilution transplantation assays [6]. In addition, *s-Ship*-expressing cap cells are strongly associated
246 with the expression of Par3L, a protein related to the cell polarity regulator Par3, which is required for MaSC
247 maintenance and ductal morphogenesis [60]. Recent mathematical modeling of mammary ductal elongation,
248 however, suggests that inwardly-migrating cap cells do not contribute to the luminal epithelial lineage, as
249 previously hypothesized [5]. Therefore, the precise contribution of these anatomically-distinct cells to ductal
250 morphogenesis requires further investigation. The relationship between cap cells in the TEB and unipotent
251 MaSCs, identified by genetic lineage-tracing [11,15,16,18], is also unclear. An answer to these important
252 questions, and a potential unifying definition of physiological MaSC potency, awaits future inducible fate-
253 mapping studies using transgenic s-SHIP and/or Par3L reporter models.

254
255 In the post-pubescent mammary gland, where TEBs have fully regressed, the location of MaSCs and their
256 niche constituents is more ambiguous (Figure 1c). It is presumed that MaSCs, left behind by elongating TEBs
257 during pubertal growth, are dispersed throughout the adult epithelial network. Here, hormonal cues stimulate
258 further branching and the formation of alveolar-like buds and lobuloalveoli during estrous cycling and in
259 pregnancy, respectively [61]. The notable absence of hormone receptors in mammary repopulating [62] and
260 MaSC-enriched basal cell populations [63] implies that paracrine interactions between hormone receptor-
261 expressing cells and stem cells guide tissue development and homeostasis [64–68]. Multiple paracrine
262 signaling pathways, including Wnt, EGFR, IGFR and RANK signaling, are reported to regulate MaSC
263 function downstream of hormone action. In addition, FGF, Hedgehog and Notch signaling have also been
264 implicated in modulating MaSC fate during different stages of mammary gland development. How the local
265 activities of these pathways are controlled by systemic changes in hormone levels, however, remains unknown
266 [69,70]. Nevertheless, the widespread distribution of hormone receptor-positive cells throughout the adult
267 mammary epithelial tree [16,71], suggests that MaSCs would be able to receive and integrate these paracrine
268 signals at most architectural locations within the ductal epithelium. Moreover, alterations in the abundance
269 and distribution of hormone receptor-positive cells with age [71], may reflect lifetime-dependent variations in
270 a putative MaSC niche.

271
272 MaSCs are thought to survive tissue remodeling during post-lactational involution, enabling further cycles of
273 expansion with each subsequent pregnancy (Figure 1c-f). It is therefore tempting to speculate that MaSCs
274 reside in the vicinity of epithelial branch points, poised to generate the lateral branches and lobuloalveolar
275 structures required for lactation. Fate-mapping studies using an alveolar-specific whey acidic protein (WAP)-
276 driven Cre have also identified a population of long-lived parity induced-mammary epithelial cells (PI-MECs)
277 that are sustained through multiple reproductive cycles [72]. These cells reside at ductal extremities in the

278 post-parous mammary gland, and contribute exclusively to the hormone receptor-negative luminal lineage in
279 subsequent pregnancies [7,72]. Intriguingly, a recent single cell lineage-tracing study has revealed unequal
280 distribution of MaSC progeny between lobuloalveolar units in lactating mammary tissue [16]. Thus, these
281 striking observations also support a model whereby an alveolar stem cell niche is positioned near bifurcation
282 sites in the mature ductal epithelium. Interestingly, increased MaSC activity during pregnancy correlates with
283 the re-expression of *s-Ship* specifically in basal cells at the tips of alveolar buds, suggesting the emergence of
284 a transient stem cell niche during lobuloalveogenesis [6].

285 *MaSC niche dynamics*

286 As described earlier in this review, distinct adult MaSCs are postulated to fulfil the proliferative and
287 homeostatic demands of the mammary gland (Figure 4) [19]. The degree to which the heterogeneity in the
288 MaSC compartment is intrinsic or a result of microenvironmental cues, however, is not known. A recent single
289 cell lineage-tracing study, which employed quantitative volumetric analysis to determine the contribution of
290 a single labeled MaSC to ductal morphogenesis, estimated that at least 35 lineage-restricted MaSCs actively
291 and stochastically contribute to the development of each major duct during puberty [16]. A subsequent study,
292 also using quantitative lineage-tracing at clonal density, put this number at 260 lineage-restricted MaSCs per
293 TEB, leading to the suggestion that most TEB cells can function as lineage-committed MaSCs [18].
294 Discrepancies between these two studies may reflect differing functional definitions of MaSCs, and the
295 quantitative and mathematical platforms and assumptions for analysis. Quantitative lineage-tracing studies
296 also suggest that molecularly heterogeneous populations of TEB-resident MaSCs function as single equipotent
297 pools, colonizing ductal branches through stochastic neutral drift dynamics [18]. Random segregation during
298 successive rounds of TEB bifurcation mediates the unequal distribution of MaSC progeny between adjacent
299 ductal structures, leading to clonal enrichment or extinction over time [18], supporting previous observations
300 of clonal labeling patterns [16]. Furthermore, single cell lineage-tracing has shown that most lactational alveoli
301 are comprised of the progeny of more than a single unipotent MaSC, indicating that a pool of lineage-restricted
302 alveolar MaSCs also contribute to alveolar morphogenesis during pregnancy and lactation [16]. These early
303 applications of quantitative and single-cell lineage-tracing approaches in the mammary gland [16,18] have
304 provided unprecedented insights into clonal dynamics and stem/progenitor heterogeneity and multiplicity,
305 heralding a new era in our investigation and understanding of normal and malignant stem cells in the breast.

306 **Concluding Remarks**

307
308 In this review we examined properties of potency, dynamics and plasticity in adult MaSCs, and the respective
309 technologies that have underpinned key experimental observations. Whilst this area has received considerable
310 attention over the last decade, many questions remain unanswered (see Outstanding Questions). At the center
311 of this enquiry is whether MaSCs in the adult breast are unipotent, bipotent or something less discordant.
312
313

314 Stem cells are defined by their functional abilities, that is: proliferation, self-maintenance, production of a
315 large number of differentiated progeny, tissue regeneration/repair, and a flexibility within these states [39].
316 The challenge thus far has been how to study a cell's functionality without inadvertently altering its function.
317 Lineage-tracing has come a long way in this respect [11–16,18]. The refinement of lineage-tracing approaches
318 and the application of other novel experimental models and methods for marking, visualizing and profiling
319 individual cells (Box 1) will continue to provide important insights in this field. The question then becomes,
320 what level of evidence is required to achieve a consensus?

321 **Acknowledgements**

322 This work was supported by the Medical Research Council (MR/J001023/1 to C.J.W. and B.L.-L.), Wellcome
323 Trust (105377/Z/14/Z to O.B.H.), the National Health and Medical Research Council (1071074 to F.M.D.)
324 and a University of Queensland Early Career Researcher Grant (UQECR1718865 to F.M.D.). We thank Dr.
325 Silvia Fre for her valuable feedback on this manuscript, and apologize to all investigators whose work could
326 not be cited owing to space limitations.

327

Glossary

Basal cell: one of the two main cell lineages in the mammary gland; basal cells surround the luminal cell layer and typically express cytokeratin-5, -14 and smooth muscle actin.

Bi/multipotent: able to give rise to more than one cell lineage, e.g., a bipotent MaSC may be able to give rise to both basal and luminal progeny.

Clone: All of the progeny of a single parent cell.

Label retaining cell: a cell that is able to retain a label (be it a lipophilic dye, DNA intercalating nucleoside or regulated-expression of a fluorescently-tagged histone) over a defined chase period. Cells that remain in cycle dilute the label, whereas slow-cycling or quiescent cells remain labeled at the end of the assay.

Lineage-tracing: a technique to identify the progeny of a single cell; the phrase “population-based lineage-tracing” has been used here to distinguish techniques that trace the progeny of specific populations of cells (e.g., cytokeratin-14-expressing cells) generally at levels higher than clonal density.

Luminal cell: one of the two main cell lineages in the mammary gland; luminal cells line the lumen of ducts and alveoli; they typically express cytokeratin-8 and may be hormone receptor positive or negative.

Mammary epithelial cell hierarchy: the organization of stem, progenitor and differentiated cells in the mammary gland.

Mammary repopulating cells: Cells enriched for the ability to regenerate the mammary epithelium upon serial transplantation at limiting dilution into the cleared fat pad of a recipient mouse.

Mammary stem cells (MaSCs): undifferentiated cells in the mammary gland that are capable of giving rise indefinitely to more stem cells (self-renewal) as well as to more-differentiated daughters through symmetric and asymmetric divisions. Uncertainties surrounding the identity, differentiation potential and plasticity of these cells has generated semantic debate, and MaSCs are also referred to more conservatively as “stem/progenitor cells”.

Potential stem cell: a more differentiated cell that is able to re-acquire stem-like properties under regenerative/wounding conditions. Also known as facultative stem cells.

Stem cell niche: the specialized microenvironment in which a stem cell resides that can regulate stem cell self-renewal, differentiation and longevity.

Terminal end bud (TEB): bulbous proliferative structures at the ends of each main duct during puberty; the presumptive location of pubertal MaSCs.

Unipotent: able to give rise to one main cell lineage, e.g., a unipotent luminal stem cell is able to give rise only to luminal progeny and a unipotent basal stem cell is able to give rise only to basal progeny.

359 **Figure Legends**

360 **Figure 1: Postnatal mammary gland development in mice.** **a)** Mammals are born with only a rudimentary
361 ductal structure (see [3] and [4] for a description of embryonic mammary gland development), which begins
362 to elongate and invade the empty fat pad at puberty (**b**). By the end of puberty (**c**), the ductal structures have
363 reached the boundaries of the mammary fat-pad and the TEBs have fully regressed. Mammary ducts are
364 comprised of two epithelial cell lineages arranged into distinct cell layers; luminal cells line the lumen of each
365 duct and are surrounded by an outer layer of basal cells (depicted inset). Whether MaSCs in the adult
366 mammary gland are lineage-restricted or can give rise to both luminal and basal cells is area of contention. **c-**
367 **e)** Resident MaSCs in the mature mammary epithelium are responsible for the generation of milk-producing
368 alveoli during pregnancy and lactation. **f)** Stem cells are likely to survive post-lactational regression
369 (involution) to enable successive pregnancies. The mouse is an excellent model for studying processes
370 regulating human mammary gland development and tumorigenesis, however, key differences exist (see [83]).
371 Notably, the human mammary gland is arranged in distinct lobes, each with a separate ductal structure and
372 outlet.

373
374 **Figure 2: A summary of the key discoveries in the field and the methodologies that enabled these**
375 **advances.** This timeline focuses on discoveries made within the last decade, using transplantation or genetic
376 lineage-tracing assays. For a more detailed historical review see [19,20,84]. Schematic diagrams summarizing
377 each *in vivo* methodology are depicted at puberty, however, these techniques have also been utilized to assess
378 cell fate at other developmental stages, and in some cases their use has also been extended to investigate
379 cellular dynamics in mammary tumorigenesis.

380
381 **Figure 3: Limitations of population-based lineage-tracing studies.** **a)** Clonal patterns arising from the
382 genetic labeling of a single cell (purple). These studies demonstrate that progeny of a single marked cell can
383 be distributed throughout the length of the ductal epithelium in a stochastic, interspersed labeling pattern.
384 These patterns are likely to be caused by the proliferation of both labeled and unlabeled TEB-resident stem
385 cells, which deposit their progeny throughout the epithelium during ductal elongation. Labeling patterns can
386 extend more than 8 mm in linear length and comprise many side branches, highlighting the importance of
387 performing 3D imaging and/or macro clone analysis. Scale bar: 0.2 mm. Adapted from Lloyd-Lewis et al.
388 Breast Cancer Research (Springer Nature) [24]. A schematic representation of these labeling patterns in
389 luminal and basal clones is shown in (**b**). The extensive and stochastic dispersion of stem cell progeny increase
390 the likelihood of clone convergence in studies where labeling is performed above clonal density. Clone
391 convergence is particularly evident when using a multi-color reporter gene. In the example here (**b**, bottom
392 panel), it is difficult to distinguish whether luminal and basal blue cells came from a single bipotent precursor,
393 or whether they arose from separate labeling events. Other technical limitations of population-based lineage-
394 tracing approaches include periodic and promiscuous labeling by pathway-specific or pan-lineage promoters.

395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412

Figure 4: A working model of the mammary epithelial cell hierarchy. Multipotent MaSCs are present in the embryo. Although the exact stage of lineage-specification is not clear, postnatal mammary gland development (i.e. ductal and alveolar morphogenesis) is principally driven by unipotent luminal and basal MaSCs. Luminal stem cells give rise to ductal and alveolar cells that can be estrogen receptor (ER) positive or negative. The extent of sub-lineage diversity in the basal compartment, and whether there are distinct ductal and alveolar basal cells, is not yet clear. In addition to the cells responsible for building mammary ducts and alveoli under physiological conditions (left panel), various studies indicate that quiescent and potential stem cells may also reside within the adult mammary gland (right panel). Quiescent bi/multipotent MaSCs (not detected by quantitative or single cell lineage-tracing approaches) may remain in the mammary gland after embryonic development. Additionally, a plastic, intermediate cell type with properties similar to the basal cell lineage may be capable of reverting to a multipotent state under regenerative conditions. Lineage-restricted luminal and basal progenitors have also been shown to reacquire multipotency with oncogenic reprogramming. A holistic description of the cellular differentiation hierarchy in the mammary gland may need to accommodate aspects of plasticity.

- 414 1 Visvader, J.E. and Clevers, H. (2016) Tissue-specific designs of stem cell hierarchies. *Nat. Cell Biol.*
415 18, 349–355
- 416 2 O’Brien, L.E. and Bilder, D. (2013) Beyond the niche: tissue-level coordination of stem cell
417 dynamics. *Annu. Rev. Cell Dev. Biol.* 29, 107–36
- 418 3 Macias, H. and Hinck, L. (2012) Mammary gland development. *Wiley Interdiscip. Rev. Dev. Biol.* 1,
419 533–557
- 420 4 Watson, C.J. and Khaled, W.T. (2008) Mammary development in the embryo and adult: a journey of
421 morphogenesis and commitment. *Development* 135, 995–1003
- 422 5 Paine, I. *et al.* (2016) A geometrically-constrained mathematical model of mammary gland ductal
423 elongation reveals novel cellular dynamics within the terminal end bud. *PLoS Comput. Biol.* 12,
424 e1004839
- 425 6 Bai, L. and Rohrschneider, L.R. (2010) s-SHIP promoter expression marks activated stem cells in
426 developing mouse mammary tissue. *Genes Dev.* 24, 1882–1892
- 427 7 Chang, T.H.-T. *et al.* (2014) New insights into lineage restriction of mammary gland epithelium using
428 parity-identified mammary epithelial cells. *Breast Cancer Res.* 16, R1
- 429 8 Stingl, J. *et al.* (2006) Purification and unique properties of mammary epithelial stem cells. *Nature*
430 439, 993–7
- 431 9 Shackleton, M. *et al.* (2006) Generation of a functional mammary gland from a single stem cell.
432 *Nature* 439, 84–8
- 433 10 Sleeman, K.E. *et al.* (2006) CD24 staining of mouse mammary gland cells defines luminal epithelial,
434 myoepithelial/basal and non-epithelial cells. *Breast Cancer Res.* 8, R7
- 435 11 Van Keymeulen, A. *et al.* (2011) Distinct stem cells contribute to mammary gland development and
436 maintenance. *Nature* 479, 189–193
- 437 12 de Visser, K.E. *et al.* (2012) Developmental stage-specific contribution of LGR5(+) cells to basal and
438 luminal epithelial lineages in the postnatal mammary gland. *J. Pathol.* 228, 300–9
- 439 13 van Amerongen, R. *et al.* (2012) Developmental stage and time dictate the fate of Wnt/ β -catenin-
440 responsive stem cells in the mammary gland. *Cell Stem Cell* 11, 387–400
- 441 14 Rios, A.C. *et al.* (2014) In situ identification of bipotent stem cells in the mammary gland. *Nature*
442 506, 322–7
- 443 15 Wuidart, A. *et al.* (2016) Quantitative lineage tracing strategies to resolve multipotency in tissue-
444 specific stem cells. *Genes Dev.* 30, 1261–77
- 445 16 Davis, F.M. *et al.* (2016) Single-cell lineage tracing in the mammary gland reveals stochastic clonal
446 dispersion of stem/progenitor cell progeny. *Nat. Commun.* 7, 13053
- 447 17 Wang, D. *et al.* (2015) Identification of multipotent mammary stem cells by protein C receptor
448 expression. *Nature* 517, 81–4

- 449 18 Scheele, C. *et al.* (2017) Identity and dynamics of mammary stem cells during branching
450 morphogenesis. *Nature*
- 451 19 Sreekumar, A. *et al.* (2015) The mammary stem cell hierarchy: a looking glass into heterogeneous
452 breast cancer landscapes. *Endocr. Relat. Cancer* 22, T161-76
- 453 20 Visvader, J.E. and Stingl, J. (2014) Mammary stem cells and the differentiation hierarchy: current
454 status and perspectives. *Genes Dev.* 28, 1143–1158
- 455 21 Nassar, D. and Blanpain, C. (2016) Cancer stem cells: basic concepts and therapeutic implications.
456 *Annu. Rev. Pathol. Mech. Dis.* 11, 47–76
- 457 22 DeOme, K.B. *et al.* (1959) Development of mammary tumors from hyperplastic alveolar nodules
458 transplanted into gland-free mammary fat pads of female C3H mice. *Cancer Res.* 19, 515–20
- 459 23 Rios, A.C. *et al.* (2016) Essential role for a novel population of binucleated mammary epithelial cells
460 in lactation. *Nat. Commun.* 7, 11400
- 461 24 Lloyd-Lewis, B. *et al.* (2016) Imaging the mammary gland and mammary tumours in 3D: optical
462 tissue clearing and immunofluorescence methods. *Breast Cancer Res.* 18, 127
- 463 25 Sale, S. and Pavelic, K. (2015) Mammary lineage tracing: The coming of age. *Cell. Mol. Life Sci.* 72,
464 1577–1583
- 465 26 Hoshino, K. (1964) Regeneration and growth of quantitatively transplanted mammary glands of
466 normal female mice. *Anat. Rec.* 150, 221–36
- 467 27 Smith, G.H. and Medina, D. (1988) A morphologically distinct candidate for an epithelial stem cell in
468 mouse mammary gland. *J. Cell Sci.* 90 (Pt 1), 173–183
- 469 28 Daniel, C. *et al.* (1968) The in vivo life span of normal and preneoplastic mouse mammary glands: a
470 serial transplantation study. *Proc. Natl. Acad. Sci. U. S. A.* 61, 53–60
- 471 29 Kordon, E.C. and Smith, G.H. (1998) An entire functional mammary gland may comprise the
472 progeny from a single cell. *Development* 125, 1921–30
- 473 30 Ehmann, U.K. *et al.* (1987) Cultured mouse mammary epithelial cells: normal phenotype after
474 implantation. *J. Natl. Cancer Inst.* 78, 751–7.
- 475 31 Smith, G.H. (1996) Experimental mammary epithelial morphogenesis in an in vivo model: Evidence
476 for distinct cellular progenitors of the ductal and lobular phenotype. *Breast Cancer Res. Treat.* 39,
477 21–31
- 478 32 Prater, M.D. *et al.* (2014) Mammary stem cells have myoepithelial cell properties. *Nat. Cell Biol.* 16,
479 942–50, 1–7
- 480 33 Van Keymeulen, A. *et al.* (2015) Reactivation of multipotency by oncogenic PIK3CA induces breast
481 tumour heterogeneity. *Nature* 525, 119–123
- 482 34 Koren, S. *et al.* (2015) PIK3CA(H1047R) induces multipotency and multi-lineage mammary
483 tumours. *Nature* 525, 114–118
- 484 35 Rios, A.C. *et al.* (2016) The complexities and caveats of lineage tracing in the mammary gland.

485 *Breast Cancer Res.* 18, 116

486 36 Rodilla, V. *et al.* (2015) Luminal Progenitors Restrict Their Lineage Potential during Mammary
487 Gland Development. *PLoS Biol.* 13,

488 37 Lafkas, D. *et al.* (2013) Notch3 marks clonogenic mammary luminal progenitor cells in vivo. *J. Cell*
489 *Biol.* 203, 47–56

490 38 Kozar, S. *et al.* (2013) Continuous clonal labeling reveals small numbers of functional stem cells in
491 intestinal crypts and adenomas. *Cell Stem Cell* 13, 626–33

492 39 Potten, C.S. and Loeffler, M. (1990) Stem cells: attributes, cycles, spirals, pitfalls and uncertainties.
493 Lessons for and from the crypt. *Development* 110, 1001–1020

494 40 Aloia, L. *et al.* (2016) Cellular plasticity in the adult liver and stomach. *J. Physiol.* 594, 4815–25

495 41 Cotsarelis, G. *et al.* (1990) Label-retaining cells reside in the bulge area of pilosebaceous unit:
496 implications for follicular stem cells, hair cycle, and skin carcinogenesis. *Cell* 61, 1329–37

497 42 Horsley, V. *et al.* (2008) NFATc1 balances quiescence and proliferation of skin stem cells. *Cell* 132,
498 299–310

499 43 Tumber, T. *et al.* (2004) Defining the epithelial stem cell niche in skin. *Science* 303, 359–63

500 44 Buczacki, S.J.A. *et al.* (2013) Intestinal label-retaining cells are secretory precursors expressing Lgr5.
501 *Nature* 495, 65–69

502 45 Ito, M. *et al.* (2005) Stem cells in the hair follicle bulge contribute to wound repair but not to
503 homeostasis of the epidermis. *Nat. Med.* 11, 1351–1354

504 46 Boras-Granic, K. *et al.* (2014) Embryonic cells contribute directly to the quiescent stem cell
505 population in the adult mouse mammary gland. *Breast Cancer Res.* 16, 487

506 47 Li, L. and Clevers, H. (2010) Coexistence of quiescent and active adult stem cells in mammals.
507 *Science* 327, 542–5

508 48 Fuchs, E. and Horsley, V. (2011) Ferreting out stem cells from their niches. *Nat. Cell Biol.* 13, 513–
509 518

510 49 dos Santos, C.O. *et al.* (2013) Molecular hierarchy of mammary differentiation yields refined markers
511 of mammary stem cells. *Proc. Natl. Acad. Sci. U. S. A.* 110, 7123–30

512 50 Cai, S. *et al.* (2017) A quiescent Bcl11b high stem cell population is required for maintenance of the
513 mammary gland. *Cell Stem Cell* 20, 247–60

514 51 Fu, N. *et al.* (2017) Identification of quiescent and spatially restricted mammary stem cells that are
515 hormone responsive. *Nat. Cell Biol.* 19, 164–76

516 52 Giraddi, R.R. *et al.* (2015) Stem and progenitor cell division kinetics during postnatal mouse
517 mammary gland development. *Nat. Commun.* 6, 8487

518 53 Inman, J.L. *et al.* (2015) Mammary gland development: cell fate specification, stem cells and the
519 microenvironment. *Development* 142, 1028–1042

520 54 Howard, B.A. and Lu, P. (2014) Stromal regulation of embryonic and postnatal mammary epithelial

521 development and differentiation. *Semin. Cell Dev. Biol.* 25–26, 43–51

522 55 Young, L.J.T. *et al.* (1971) The influence of host and tissue age on life span and growth rate of

523 serially transplanted mouse mammary gland. *Exp. Gerontol.* 6, 49–56

524 56 Chepko, G. and Smith, G.H. (1997) Three division-competent, structurally-distinct cell populations

525 contribute to murine mammary epithelial renewal. *Tissue Cell* 29, 239–253

526 57 Chepko, G. and Dickson, R.B. (2003) Ultrastructure of the putative stem cell niche in rat mammary

527 epithelium. *Tissue Cell* 35, 83–93

528 58 Williams, J.M. and Daniel, C.W. (1983) Mammary ductal elongation: differentiation of

529 myoepithelium and basal lamina during branching morphogenesis. *Dev. Biol.* 97, 274–90

530 59 Srinivasan, K. *et al.* (2003) Netrin-1/neogenin interaction stabilizes multipotent progenitor cap cells

531 during mammary gland morphogenesis. *Dev. Cell* 4, 371–382

532 60 Huo, Y. and Macara, I.G. (2014) The Par3-like polarity protein Par3L is essential for mammary stem

533 cell maintenance. *Nat. Cell Biol.* 16, 529–537

534 61 Brisken, C. and O'Malley, B. (2010) Hormone action in the mammary gland. *Cold Spring Harb.*

535 *Perspect. Biol.* 2, a003178

536 62 Sleeman, K.E. *et al.* (2007) Dissociation of estrogen receptor expression and in vivo stem cell activity

537 in the mammary gland. *J. Cell Biol.* 176, 19–26

538 63 Asselin-Labat, M.-L. *et al.* (2006) Steroid hormone receptor status of mouse mammary stem cells. *J.*

539 *Natl. Cancer Inst.* 98, 1011–1014

540 64 Beleut, M. *et al.* (2010) Two distinct mechanisms underlie progesterone-induced proliferation in the

541 mammary gland. *Proc. Natl. Acad. Sci. U. S. A.* 107, 2989–94

542 65 Asselin-Labat, M.-L. *et al.* (2010) Control of mammary stem cell function by steroid hormone

543 signalling. *Nature* 465, 798–802

544 66 Cai, C. *et al.* (2014) R-spondin1 is a novel hormone mediator for mammary stem cell self-renewal.

545 *Genes Dev.* 28, 2205–2218

546 67 Rajaram, R.D. *et al.* (2015) Progesterone and Wnt4 control mammary stem cells via myoepithelial

547 crosstalk. *EMBO J.* 34, 641–652

548 68 Joshi, P. a *et al.* (2010) Progesterone induces adult mammary stem cell expansion. *Nature* 465, 803–7

549 69 Rosen, J.M. and Roarty, K. (2014) Paracrine signaling in mammary gland development: what can we

550 learn about intratumoral heterogeneity? *Breast Cancer Res.* 16, 202

551 70 Brisken, C. and Ataca, D. (2015) Endocrine hormones and local signals during the development of

552 the mouse mammary gland. *Wiley Interdiscip. Rev. Dev. Biol.* 4, 181–195

553 71 Ismail, P.M. *et al.* (2002) A novel LacZ reporter mouse reveals complex regulation of the

554 progesterone receptor promoter during mammary gland development. *Mol. Endocrinol.* 16, 2475–89

555 72 Wagner, K.-U. *et al.* (2002) An adjunct mammary epithelial cell population in parous females: its role

556 in functional adaptation and tissue renewal. *Development* 129, 1377–86

557 73 Tainaka, K. *et al.* (2014) Whole-body imaging with single-cell resolution by tissue decolorization.
558 *Cell* 159, 911–924

559 74 Ke, M.-T. *et al.* (2013) SeeDB: a simple and morphology-preserving optical clearing agent for
560 neuronal circuit reconstruction. *Nat. Neurosci.* 16, 1154–61

561 75 Davis, F.M. *et al.* (2015) Essential role of Orai1 store-operated calcium channels in lactation. *Proc.*
562 *Natl. Acad. Sci. U. S. A.* 112, 5827–32

563 76 Ritsma, L. *et al.* (2013) Surgical implantation of an abdominal imaging window for intravital
564 microscopy. *Nat. Protoc.* 8, 583–94

565 77 Zomer, A. *et al.* (2013) Intravital imaging of cancer stem cell plasticity in mammary tumors. *Stem*
566 *Cells* 31, 602–6

567 78 Kumar, P. *et al.* (2017) Understanding development and stem cells using single cell-based analyses of
568 gene expression. *Development* 144, 17–32

569 79 McKenna, A. *et al.* (2016) Whole-organism lineage tracing by combinatorial and cumulative genome
570 editing. *Science* 353, aaf7907

571 80 Perli, S.S.D. *et al.* (2016) Continuous genetic recording with self-targeting CRISPR-Cas in human
572 cells. *Science* 511, 53058

573 81 Clevers, H. (2016) Modeling Development and Disease with Organoids. *Cell* 165, 1586–97

574 82 Jardé, T. *et al.* (2016) Wnt and Neuregulin1/ErbB signalling extends 3D culture of hormone
575 responsive mammary organoids. *Nat. Commun.* 7, 13207

576 83 Cardiff, R.D. and Wellings, S.R. (1999) The comparative pathology of human and mouse mammary
577 glands. *J. Mammary Gland Biol. Neoplasia* 4, 105–122

578 84 Oakes, S.R. *et al.* (2014) The mammary cellular hierarchy and breast cancer. *Cell. Mol. Life Sci.* 71,
579 4301–4324

580